Twist Bioscience Corp. Stock News

Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and EGS Officer Dr. Emily Leproust -

Twist makes synthetic biology and next-generation sequencing tools. The company reported improved revenue and reduced losses in the quarter.

Twist Bioscience (TWST) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $1.08 per share a year ago.

Cathie Wood's Ark Innovation ETF has been blazing the comeback trail in 2023. Among the fund's various holdings, Twist Biosciences and Exact Sciences stand out as top growth plays right now.

The stock of Twist Bioscience Corporation has declined more than 60% since our first peek at it in the fall of last year. However, the stock saw its first insider buy in a year last week, and the comp

Biology is the study of life. And synthetic biology is the creation of new life for new purposes.

Twist Bioscience Corporation (NASDAQ:TWST ) Q2 2023 Earnings Conference Call May 5, 2023 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs and ESG Officer Emily Leproust - CEO an

Twist Bioscience (TWST) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $1.24 per share a year ago.

Beam Therapeutics is a pioneer in base editing, an especially promising type of gene editing. CRISPR Therapeutics could soon bring the first CRISPR gene-editing therapy to market.

Cathie Wood bought shares of Roblox, Coinbase, and Twist Biosciences on Monday. Roblox is posting year-over-year growth, but profitability is still years away unless it can improve the monetization of

Personalized medicine stocks are hot right now. This form of medicine based on the particular genes, proteins, and other substances in a person's body.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon

Twist Bioscience (TWST) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could m

Since the biotech bonanza of the pandemic era, many biotech stocks have rocketed up and then down in price. Ginkgo Bioworks (NYSE: DNA ), Twist Bioscience (NASDAQ: TWST ), and Amyris (NASDAQ: AMRS ) a

Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).